The stock of SinglePoint, Inc (OTCMKTS:SING) closed at $0.073 losing 8.25% in yesterday’s trading session. This provider has recently been seen to pay much focus to accelerated growth in Cannabis sector and it targets to make its impact felt globally.

One of its greatest moves has been the signing of a letter of intent in which it expressed its interest towards the acquisition of Dr. FeelGood. This is a rather profitable medical marijuana distribution that has for pretty long indicated its commitment to setting up a proprietary delivery and ordering technology. SinglePoint remains optimistic that the new acquisition will help towards boosting it revenue stream.

The provider is confident of closing this acquisition soon and that will give a proper demonstration of the company’s ability to develop its portfolio of investments in established high-growth, high-potential cannabis enterprises. Earlier this year, this company succeeded in the acquisition of some two companies and asserts that the latest acquisition will be a significant addition to its portfolio.

SinglePoint CEO, Greg Lambrecht opined, “We are well capitalized to continue acquisitions and we are optimistic to complete around three more acquisitions and significantly increase the company’s revenue.”

He added that the company was in a better position, something that they have been looking forward to for quite long.

The President of Dewmar International BMC Inc (OTCMKTS:DEWM), J.D. Houston has expressed his willingness to attend the upcoming conference. The MJAC 2017 will be providing the various retail investors with a perfect opportunity to access crucial business insight on firms in the cannabis sector.

The shareholders that will be attending the meeting will learn much regarding Dewmar’s cannabis business setup from revenue generating services and products to portfolio of IP assets. The president is also expected to have a word with managers of micro-cap funds who have indicated their interest towards investing in firms like Dewmar.

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) recently gave its latest update on the Q3 2017 Financial Performance. The NDA filing procedure for Epidiolex is already up and running and most probably by October the final sections of the filing will be at the verge of completion.